Document Type : Original Article


Department of Basic Science, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran


Cancer is one of the main reasons of mortality all over the world. Over the time, the major ways for cancer-therapy were based on radiotherapy, chemotherapy and surgery. These methods are not specific enough for that purpose, therefore, new ideas for design of new drugs with higher specificity are considered. Chimeric protein toxins are hybrid proteins consisting of a targeting portion and a toxic one which specifically bind and kill the target cancer cells. The main purpose of this study was designing a recombinant chimeric toxin with biding capability to one of the most key receptors namely claudin-4 which is over-expressed in almost all cancer cells. To design it, we utilized the last 30 C-terminal amino acids of Clostridium perfringens enterotoxin (CPE) as a binding module for claudin-4 and the toxic module which is the A-domain of Shiga toxin from Shigella dysenteriae. Using molecular modeling and docking methods, appropriate binding affinity of the recombinant chimeric toxin to its specific receptor was demonstrated. In the next step, the stability of this interaction was investigated by molecular dynamics simulation. Although partial instability was detected at some time points, however, sufficient stable situation of hydrogens bonds and high binding affinity between the chimeric toxin and receptor were observed in the in silico studies which in turn suggested that this complex could be formed successfully.


  1. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: An overview. Int J Cancer 2021; 149(4):778-789.
  2. Hassanpour SH, Dehghani M. Review of cancer from perspective of molecular. J Cancer Res Pract 2017; 4(4):127-129.
  3. Polito L, Djemil A, Bortolotti M. Plant toxin-based immunotoxins for cancer therapy: a short overview. Biomedicines 2016; 4(2): 12. doi: 10.3390/ biomedicines4020012.
  4. Goleij Z, Mahmoodzadeh Hosseini M, Amin M, et al. In silico evaluation of two targeted chimeric proteins based on bacterial toxins for breast cancer therapy. Int J Cancer Manag 2019; 12(2): e83315. doi: 10.5812/ ijcm.83315.
  5. Morrison AJ. Cancer cell metabolism connects epigenetic modifications to transcriptional regulation. FEBS J 2022; 289(5):1302-1314.
  6. Günzel D, Yu AS. Claudins and the modulation of tight junction permeability. Physiol Rev 2013; 93(2): 525-569.
  7. Rangel LB, Agarwal R, D’Souza T, et al. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 2003; 9(7): 2567-2575.
  8. Ouban A, Ahmed AA. Claudins in human cancer, a review. Histol Histopathol 2010; 25(1): 83-90.
  9. Van Itallie CM, Anderson JM. Claudins and epithelial paracellular transport. Annu Rev Physiol 2006; 68: 403-429.
  10. Hashimi SM, Yu S, Alqurashi N, et al. Immunotoxin-mediated targeting of claudin-4 inhibits the proliferation of cancer cells. Int J Oncol 2013; 42(6):1911-1918.
  11. Vecchio AJ, Rathnayake SS, Stroud RM. Structural basis for Clostridium perfringens enterotoxin targeting of claudins at tight junctions in mammalian gut. Proc Natl Acad Sci USA 2021; 118(15):e2024651118. doi: 10.1073/pnas.2024651118.
  12. Orlando BJ, Dominik PK, Roy S, et al. Development, structure, and mechanism of synthetic antibodies that target claudin and Clostridium perfringens enterotoxin complexes. J Biol Chem 2022; 298(9): 102357. doi: 10.1016/j.jbc.2022.102357.
  13. Sandvig K, Bergan J, Dyve AB, et al. Endocytosis and retrograde transport of Shiga toxin. Toxicon 2010; 56(7): 1181-1185.
  14. Endo Y, Tsurugi K, Yutsudo T, et al. Site of action of a Vero toxin (VT2) from Escherichia coli O157: H7 and of Shiga toxin on eukaryotic ribosomes: RNA N‐glycosidase activity of the toxins. Eur J Biochem 1988; 171(1‐2): 45-50.
  15. Melton‐Celsa AR. Shiga toxin (Stx) classification, structure, and function. Microbiol Spectr 2014; 2(4): EHEC-0024-2013. doi: 10.1128/microbiolspec.EHEC-0024-2013.
  16. Mitchell LA, Koval M. Specificity of interaction between Clostridium perfringens enterotoxin and claudin-family tight junction proteins. Toxins (Basel) 2010; 2(7): 1595-1611.
  17. Ebihara C, Kondoh M, Hasuike N, et al. Preparation of a claudin-targeting molecule using a C-terminal fragment of Clostridium perfringens J Pharmacol Exp Ther 2006; 316(1): 255-260.
  18. Nair AS. Computational biology & bioinformatics: a gentle overview. CSI Communications 2007; 2: 1-12.
  19. Baldi A. Computational approaches for drug design and discovery: An overview. Sys Rev Pharm 2010; 1(1): 99-105.
  20. Heo L, Park H, Seok C. GalaxyRefine: Protein structure refinement driven by side-chain repacking. Nucleic Acids Res 2013; 41(Web Server issue): W384-W388.
  21. Guedes IA, de Magalhães CS, Dardenne LE. Receptor–ligand molecular docking. Biophys Rev 2014; 6(1): 75-87.
  22. de Vries SJ, van Dijk M, Bonvin AM. The HADDOCK web server for data-driven biomolecular docking. Nat Protoc 2010; 5(5): 883-897.
  23. Yan Y, Zhang D, Zhou P, et al. HDOCK: a web server for protein–protein and protein–DNA/RNA docking based on a hybrid strategy. Nucleic Acids Res 2017; 45(W1): W365- W373.
  24. Meller J. Molecular dynamics. eLS 2001. doi: 10.1038/ npg.els.0003048.
  25. Souod N, Rismani E, Bahrami F, et al. Computational evaluation of a fusion protein consisted of pertussis toxin and filamentous hemagglutinin from Bordetella pertussis to target Claudin-4 using C-terminal fragment of Clostridium perfringens J Biomol Struct Dyn 2021; 39(16): 5910-5919.
  26. Adil MS, Narayanan SP, Somanath PR. Cell-cell junctions: structure and regulation in physiology and pathology. Tissue Barriers 2021; 9(1): 1848212. doi: 10.1080/21688370.2020.1848212.
  27. Nighot P, Ma T. Endocytosis of intestinal tight junction proteins: in time and space. Inflamm Bowel Dis 2021; 27(2): 283-290.
  28. Shashikanth N, France MM, Xiao R, et al. Tight junction channel regulation by interclaudin interference. Nat Commun 2022; 13(1):3780. doi: 10.1038/s41467-022-31587-8.
  29. Coulson A, Levy A, Gossell-Williams Monoclonal anti-bodies in cancer therapy: mechanisms, successes and limitations. West Indian Med J 2014; 63(6): 650-654.